NO167076C - Fremgangsmaate til fremstilling av et immunogent kompleks som kan anvendes til immunostimulerende preparat, vaksine og reagens. - Google Patents

Fremgangsmaate til fremstilling av et immunogent kompleks som kan anvendes til immunostimulerende preparat, vaksine og reagens.

Info

Publication number
NO167076C
NO167076C NO854355A NO854355A NO167076C NO 167076 C NO167076 C NO 167076C NO 854355 A NO854355 A NO 854355A NO 854355 A NO854355 A NO 854355A NO 167076 C NO167076 C NO 167076C
Authority
NO
Norway
Prior art keywords
peptides
proteins
complex
reagents
carrier molecule
Prior art date
Application number
NO854355A
Other languages
English (en)
Other versions
NO167076B (no
NO854355L (no
Inventor
Bror Morein
Original Assignee
Bror Morein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morein filed Critical Bror Morein
Publication of NO854355L publication Critical patent/NO854355L/no
Publication of NO167076B publication Critical patent/NO167076B/no
Publication of NO167076C publication Critical patent/NO167076C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO854355A 1984-11-01 1985-10-31 Fremgangsmaate til fremstilling av et immunogent kompleks som kan anvendes til immunostimulerende preparat, vaksine og reagens. NO167076C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8405493A SE8405493D0 (sv) 1984-11-01 1984-11-01 Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel

Publications (3)

Publication Number Publication Date
NO854355L NO854355L (no) 1986-05-02
NO167076B NO167076B (no) 1991-06-24
NO167076C true NO167076C (no) 1991-10-02

Family

ID=20357588

Family Applications (1)

Application Number Title Priority Date Filing Date
NO854355A NO167076C (no) 1984-11-01 1985-10-31 Fremgangsmaate til fremstilling av et immunogent kompleks som kan anvendes til immunostimulerende preparat, vaksine og reagens.

Country Status (17)

Country Link
US (1) US5254339A (no)
EP (2) EP0180564B1 (no)
JP (2) JPH07116056B2 (no)
AT (1) ATE65186T1 (no)
AU (2) AU589915B2 (no)
CA (2) CA1275042A (no)
DE (1) DE3583485D1 (no)
DK (1) DK166653B1 (no)
ES (1) ES8701497A1 (no)
FI (1) FI86801C (no)
IE (1) IE58530B1 (no)
NO (1) NO167076C (no)
NZ (1) NZ213899A (no)
PT (1) PT81384B (no)
SE (1) SE8405493D0 (no)
WO (1) WO1987002250A1 (no)
ZA (1) ZA858157B (no)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5314642A (en) * 1984-11-27 1994-05-24 Igen, Inc. Interaction system comprising a surfactant-stabilized aqueous phase containing an antibody fragment
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
FR2598434B1 (fr) * 1986-05-12 1988-09-16 Pf Medicament Nouveaux immunomodulateurs obtenus par hemisynthese a partir d'un polysaccharide bacterien isole d'une souche mutante non capsulee de klebsiella pneumoniae
US4888169A (en) * 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
EP0270295A3 (en) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Conjugate vaccine
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
FR2614306B1 (fr) * 1987-04-22 1989-07-28 Pf Medicament Nouveau derive de d.25, procede de preparation, utilisation a titre d'agent immunostimulant et compositions pharmaceutiques le contenant.
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
DE3727987A1 (de) * 1987-08-21 1989-03-02 Sleytr Uwe B Pharmazeutische struktur
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
JPH049015U (no) * 1990-05-09 1992-01-27
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
DE69229476T2 (de) * 1991-08-15 2000-03-16 Smithkline Beecham Biolog Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
GB9207731D0 (en) * 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
EP0604727A1 (en) * 1992-12-31 1994-07-06 American Cyanamid Company Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
CA2158651C (en) * 1993-03-29 2009-09-01 David S. Roberts Multicomponent clostridial vaccines using saponin adjuvants
JPH0756123A (ja) * 1993-08-20 1995-03-03 Nakanishi Opt:Kk 眼鏡フレーム
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0805855B1 (en) * 1995-01-27 2007-02-28 Genencor International, Inc. Surfactant-based enzyme extraction process
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
US20030190323A1 (en) * 1995-07-05 2003-10-09 Yeda Research And Development Co. Ltd. Preparations and methods for the treatment of T cell mediated diseases
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
CA2267207C (en) 1997-08-04 2008-10-28 Tonen Corporation Methods for detecting or assaying virus
ID29082A (id) * 1998-09-22 2001-07-26 Molecular Express Inc Komposisi liposom imunogenik
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
US7776343B1 (en) * 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
KR20060134225A (ko) 1999-04-09 2006-12-27 파마시아 앤드 업존 캄파니 엘엘씨 항균성 백신 조성물
AU5695701A (en) 2000-03-17 2001-10-03 Upjohn Co Salmonella vaccine materials and methods
US6764823B2 (en) 2000-04-06 2004-07-20 Pharmacia & Upjohn Company Antimicrobial methods and materials
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US7094351B2 (en) 2000-10-12 2006-08-22 Corcoran Robert C Purification of substances by reaction affinity chromatography
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
WO2013034682A1 (en) 2011-09-08 2013-03-14 Umc Utrecht Holding B.V. Vaccine based on staphylococcal superantigen- line 3 protein (ssl3)
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003074068A2 (en) * 2002-03-01 2003-09-12 Trillium Therapeutics Inc. Use of soluble fgl2 as an immunosuppressant
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
CA2494197C (en) 2002-08-12 2012-10-09 Akzo Nobel N.V. Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
DE60335742D1 (de) 2002-11-20 2011-02-24 Bestewil Holding Bv Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
CA2565500A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
EP1896067B1 (en) 2005-06-16 2011-07-20 Universiteit Gent Vaccines for immunization against helicobacter
EP1912665B1 (en) 2005-07-28 2011-01-26 Pfizer Products Inc. Vaccine against feline calicivirus (fcv) comprising a fcv capsid protein or an isolated fcv capsid protein comprising protein sequence seq id no: 13 or protein sequences having at least 95% identity thereto.
KR20080042174A (ko) 2005-10-07 2008-05-14 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20100028379A1 (en) 2006-12-27 2010-02-04 Pfizer, Inc Methods of vaccine administration
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
KR20110004354A (ko) * 2007-12-21 2011-01-13 와이어쓰 엘엘씨 유전자 변형된 약독화 수포성 구내염 바이러스, 이의 조성물 및 사용 방법
WO2009155484A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
MX2012000044A (es) 2009-06-22 2012-01-30 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
BR112012009309B1 (pt) 2009-10-19 2021-10-05 Intervet International B.V Vacina combinada, uso de células de microrganismos,método para a preparação de uma vacina combinada, e, kit de partes
CN102711816A (zh) 2009-10-22 2012-10-03 莱比锡大学 患有牛新生儿全血细胞减少症的小牛中的圆环病毒的检测
ES2588225T3 (es) 2010-04-21 2016-10-31 Pharmaq As Secuencias de ácido nucleico de un virus de pece y el uso de las mismas
US8623375B2 (en) 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
SI3170508T1 (sl) 2010-06-04 2020-01-31 Wyeth Llc Formulacije cepiva
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
CN107281478B (zh) 2010-07-23 2022-04-01 诺瓦瓦克斯公司 流感疫苗
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012059593A1 (en) 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
CA2817933A1 (en) 2010-11-15 2012-05-24 Pharmaq As New salmon calicivirus isolate
WO2012076668A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
ES2614815T3 (es) 2010-12-22 2017-06-02 Wyeth Llc Composiciones inmunogénicas estables de antígenos de Staphylococcus aureus
US20130287786A1 (en) 2010-12-29 2013-10-31 Theodorus Petrus Maria Schetters Canine babesiosis vaccine antigen
US9139618B2 (en) 2010-12-29 2015-09-22 Intervet Inc. Salmonid alphavirus protein E2
WO2012131099A1 (en) 2011-03-31 2012-10-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
MX348380B (es) 2011-04-07 2017-06-09 Neovacs Pruducto inmunogénico para usarse en vacunas.
PT2707025T (pt) 2011-05-13 2017-08-31 Zoetis Services Llc Composições imunogénicas contra a glicoproteína g de vírus hendra e nipah
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
JP6275641B2 (ja) * 2011-07-20 2018-02-07 ビージーピー プロダクツ ベー ブイ ウイルス抗原およびワクチンの製造方法
EP4176871A1 (en) 2011-10-03 2023-05-10 Canqura Oncology Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN104640563A (zh) 2012-07-27 2015-05-20 巴克斯特国际公司 包含嵌合的ospa分子的组合物及其使用方法
PL3363806T3 (pl) 2012-12-20 2022-12-19 Pfizer Inc. Sposób glikokoniugacji
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP2978448B1 (en) 2013-03-26 2018-05-30 The Pirbright Institute Stabilised fmdv capsids
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3082856A1 (en) 2013-12-16 2016-10-26 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
ES2702325T3 (es) 2014-03-11 2019-02-28 Univ Minnesota Vacunas contra el virus de la diarrea epidémica porcina y métodos de uso de las mismas
ES2788393T3 (es) 2014-09-03 2020-10-21 Intervet Int Bv Coronavirus de bovino atenuado y vacunas relacionadas
EP3200820B1 (en) 2014-10-03 2023-07-05 Intervet International B.V. Broad-spectrum vaccine against avian reovirus
EP3207055A1 (en) 2014-10-15 2017-08-23 Xenothera Composition with reduced immunogenicity
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2016144962A1 (en) 2015-03-10 2016-09-15 Bio-Rad Laboratories, Inc. Combination treponemal and non-treponemal syphilis test
IL255106B2 (en) 2015-05-04 2023-04-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses
RU2730625C2 (ru) 2015-09-03 2020-08-24 Новавакс, Инк. Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
EP3500292A1 (en) 2016-08-17 2019-06-26 Pharmaq AS Sea lice vaccine
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
CN111108193A (zh) 2017-09-18 2020-05-05 拜耳医药保健有限公司 使用n-甲基葡糖酰胺及其衍生物灭活病毒的方法
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20230146256A1 (en) 2020-04-17 2023-05-11 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2022136505A1 (en) 2020-12-23 2022-06-30 Xenothera Composition of pig polyclonal antibody for its use to treat and/or prevent antibody-dependent macrophage pro-inflammatory cytokine release in a passive anti-infectious immunotherapy
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2023225458A1 (en) 2022-05-16 2023-11-23 Zoetis Services Llc Vaccines against moritella viscosa
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4136167A (en) * 1975-06-12 1979-01-23 Internationale Octrooi Maatschappij "Octropa" B.V. Process for reducing the incidence of neonatal diarrhoea in pigs
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4201767A (en) * 1978-11-08 1980-05-06 Merck & Co., Inc. Viral liposome particle
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
EP0047480B1 (en) * 1980-09-05 1986-02-05 Institut Armand Frappier Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
GB2104527B (en) * 1981-08-24 1985-10-02 Vilas V Likhite Antingens as immunostimulant adjuvants
US4429008B1 (en) * 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
EP0142192A1 (en) * 1983-10-22 1985-05-22 Akzo N.V. Preparation of immunogens consisting of antigenic determinates bound to glycoside-containing carriers
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
DE3617978A1 (de) * 1986-05-28 1987-12-03 Bayer Ag Verzweigte thermoplastische polycarbonate mit verbessertem schutz gegen uv-licht
US6578143B1 (en) * 1998-12-18 2003-06-10 Qualcomm Incorporated Method for negotiating weakened keys in encryption systems
FR2788649A1 (fr) * 1999-01-18 2000-07-21 Schlumberger Systems & Service Procede de chargement securise de donnees entre des modules de securite
FI20075083A0 (fi) * 2007-02-06 2007-02-06 Nokia Corp Ilmaisumenetelmä ja -laite monivuo-MIMOa varten

Also Published As

Publication number Publication date
JPS63501078A (ja) 1988-04-21
AU590904B2 (en) 1989-11-23
PT81384A (en) 1985-11-01
FI854158A0 (fi) 1985-10-23
JPH0751514B2 (ja) 1995-06-05
JPH07116056B2 (ja) 1995-12-13
DK498585A (da) 1986-05-02
AU589915B2 (en) 1989-10-26
CA1275042A (en) 1990-10-09
PT81384B (pt) 1987-11-11
IE58530B1 (en) 1993-10-06
IE852672L (en) 1986-05-01
NO167076B (no) 1991-06-24
EP0180564A2 (en) 1986-05-07
FI86801B (fi) 1992-07-15
NZ213899A (en) 1988-10-28
ZA858157B (en) 1986-06-25
EP0180564A3 (en) 1988-06-01
ES8701497A1 (es) 1986-12-01
EP0242380B1 (en) 1991-04-03
ES548412A0 (es) 1986-12-01
AU4938385A (en) 1986-05-08
ATE65186T1 (de) 1991-08-15
EP0242380A1 (en) 1987-10-28
JPS61129136A (ja) 1986-06-17
FI854158L (fi) 1986-05-02
EP0180564B1 (en) 1991-07-17
NO854355L (no) 1986-05-02
US5254339A (en) 1993-10-19
DK498585D0 (da) 1985-10-30
CA1275246C (en) 1990-10-16
SE8405493D0 (sv) 1984-11-01
WO1987002250A1 (en) 1987-04-23
FI86801C (fi) 1992-10-26
DE3583485D1 (de) 1991-08-22
AU6475286A (en) 1987-05-05
DK166653B1 (da) 1993-06-28

Similar Documents

Publication Publication Date Title
NO167076C (no) Fremgangsmaate til fremstilling av et immunogent kompleks som kan anvendes til immunostimulerende preparat, vaksine og reagens.
Martin et al. The chromatographic fractionation of ribonuclease
SE8205892D0 (sv) Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
Kandutsch et al. PARTIAL PURIFICATION OF TISSUE ISOANTIGENS FROM A MOUSE SARCOMA1, 2
Sage et al. Studies on a hemagglutinin from the mushroom Agaricus campestris
Liu et al. Influence of ultrasonication prior to glycation on the physicochemical properties of bovine serum albumin–galactose conjugates
Fishkin et al. Isolation of a glycoprotein from granulation tissue in rats
Knowles et al. Isolation and characterization of proteolipids from sarcoplasmic reticulum
Barraco et al. Paleobiochemical analysis of an Egyptian mummy
SLOMIANY et al. ABH‐Blood‐Group Antigens and Glycolipids of Human Saliva
Pierce Countercurrent distribution studies on anterior pituitary growth hormone
Myers et al. Separation of glomerular basement membrane substances by sodium dodecylsulfate disc gel electrophoresis and gel filtration
Liu et al. Observation of the structural changes of α‐lactalbumin induced by ultrasonic prior to glycated modification
CN104730236A (zh) 一种蛋白质固定试剂及其应用
Azuma et al. Studies on Pig Serum Lipoproteins: I. Separation and Properties of Low-density Lipoproteins
Pasieka et al. Antibody production in goat milk serum after virus instillation of goat mammary gland. V. Biochemical isolation and further characterization of antibodies to various influenza and mumps viruses
Antonyuk et al. Carbohydrate specificity of lectin, purified from the fruiting bodies of Mycena pura/Fr./Kumm. and its use in histochemical investigation
De Bruijn A simplified method for the preparation of Reiter protein antigen
Pardoe et al. Preparation of erythrocyte receptors for viruses by affinity chromatography
Nuck Enzymatical hydrolysis of N-glycans from glycoproteins and fluorescent labeling by 2-aminobenzamide (2-AB)
Tanford State of association of membrane proteins
CN117571983A (zh) 碱性磷酸酶快速标记试剂盒及方法
Alvarado Quiroz Characterization of marine exopolymeric substance (EPS) responsible for binding of thorium (IV) isotopes
Wallach et al. Membrane “Macromolecules”
Quiroz Characterization of Marine Exopolymeric Substance (EPS) Responsible for Binding of Thorium (IV) Isotopes

Legal Events

Date Code Title Description
MK1K Patent expired